May 1997
Physical Therapy;May1997, Vol. 77 Issue 5, pS78
Academic Journal
Presents an abstract of a paper entitled `Evaluation of Neurogenic Claudication and Functional Result of Treatment Using the Treadmill-Bicycle Test,' by P. Gupta, J. Tenhula et al, presented at the Physical Therapy `97: Scientific Meeting and Exposition of the American Physical Therapy Association.


Related Articles

  • Treatment of Long-Distance Intermittent Claudication with Pentoxifylline: A 12-Month, Randomized Trial. De Sanctis, M.T.; Cesarone, M.R.; Belcaro, G.; Nicolaides, A.N.; Griffin, M.; Incandela, L.; Bucci, M.; Geroulakos, G.; Ramaswami, G.; Vasdekis, S.; Agus, G.; Bavera, P.; Ippolito, E. // Angiology;Jan/Feb2002 Supplement, Vol. 53, pS13 

    Examines patients with intermittent claudification in a double-blind, randomized, placebo-controlled trial. Therapeutic use of pentoxifylline (PXF) in the treatment of intermittent claudification; Effectiveness of PXF; Administration of a standardized treadmill test to patients.

  • Comparação entre os métodos subjetivo e objetivo para avaliação da capacidade funcional durante tratamento clínico em pacientes com claudicação intermitente. Cucato, Gabriel Grizzo; Zerati, Antônio Eduardo; da Rocha Chehuen, Marcel; Ritti-Dias, Raphael Mendes; Saez, Glauco; Ragazzo, Luciana; Puech-Leão, Pedro; Wolosker, Nelson // Einstein (16794508);out/dez2013, Vol. 11 Issue 4, p495 

    Objective: To analyze if there is any relation between functional capacity assessed by subjective and objective methods regarding the current state and after clinical treatment in patients with intermittent claudication. Methods: A total of 500 patients with intermittent claudication were...

  • Long-Term Evaluation of Indobufen in Peripheral Vascular Disease. Belcaro, G.; De Simone, P. // Angiology;Jan1991, Vol. 42 Issue 1, p8 

    Indobufen�an inhibitor of platelets aggregation�has been used in 306 patients with intermittent claudication due to peripheral vascular disease. Patients were treated and followed up for one year. One patient of every 3 treated with indobufen was treated with ASA, and a control group...

  • Trial of a novel prostacyclin analog, UT-15, in patients with severe intermittent claudication. Mohler III, E.R.; Klugherz, B.; Goldman, R.; Kimmel, S.E.; Wade, M.; Sehgal, C.M. // Vascular Medicine;2000, Vol. 5 Issue 4, p231 

    Prostacyclin is an endothelially derived vasodilator and inhibitor of platelet aggregation. Despite its therapeutic potential for peripheral arterial disease, the short half-life and chemical instability are barriers to routine therapy. Accordingly, prostacyclin analogs are being evaluated in...

  • Walk away from leg pain.  // Consumer Reports on Health;Apr96, Vol. 8 Issue 4, p46 

    Reports that older persons with clogged arteries in their legs get pains in their calves when they walk which is called intermittent claudication. Treatment for intermittent claudication; Exercise programs for claudication pain.

  • Naftidrofuryl for intermittent claudication: a double-blind controlled trial. Ruckley, C.V.; Callam, M.J.; Ferrington, C.M.; Prescott, R.J. // British Medical Journal;3/11/1978, Vol. 1 Issue 6113, p622 

    Intermittent claudication is the commonest symptom of an increasingly common disorder: obliterative arterial disease affecting the legs. Hitherto, despite the wide pharmaceutical range offered, there has been little medical treatment of proved value to prescribe and, in particular, vasodilator...

  • Pletal gets the green light for intermittent claudication. Cerrato, Paul L. // RN;Apr99, Vol. 62 Issue 4, p96 

    Reports on the United States Food and Drug Administration's approval of cilostazol for treatment of intermittent claudication. Indications.

  • Effect of cloricromene on intermittent claudication. A randomized, double-blind, placebo-controlled trial in patients treated with aspirin: effect on claudication distance and quality of life. Gresele, P.; Migliacci, R.; Nenci, G.G.; Di Sante, G. // Vascular Medicine;2000, Vol. 5 Issue 2, p83 

    The main aim of medical treatment for intermittent claudication (IC) is the reduction of mortality and morbidity from ischemic cardiovascular disease. However, symptomatic treatment with the aim of improving exercise performance and the overall quality of life may also be an important target of...

  • Drug offers relief for patients with painful leg ailment. Portyansky, Elena // Drug Topics;2/15/99, Vol. 143 Issue 4, p20 

    Focuses the on the drug Pletal or cilostazol designed for the reduction of the symptoms of intermittent claudication (IC). Performance of the drug in clinical trials; Issue on the drug's ability to reduce the progression of the IC condition; Caution in using the drug. INSET: Tips to Remember.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics